newsfilter
← Latest News
GlobeNewswire·

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

  • YD Bio Limited (NASDAQGM: YDES) rang the Nasdaq Opening Bell on Oct. 20, 2025, to celebrate its listing on the Nasdaq Global Market.
  • The public listing aims to strengthen the company's capital base, elevate its global profile, & accelerate commercialization of its diagnostic & regenerative medicine platforms.
  • Dr. Ethan Shen, Chairman & CEO, highlighted exclusive 20-year licenses from EG Biomed & 3D Global Biotech as key strategic assets for scaling non-invasive cfDNA methylation cancer tests & exosome-based eye therapies.
  • The expanded access to U.S. capital markets is intended to turbocharge R&D, grow the Seattle-based CLIA & CAP certified laboratory, & fuel the launch of pipeline products.
  • Founded in 2013, YD Bio evolved from a clinical trial drug supplier into a diversified biotech innovator leveraging alliances with EG BioMed & 3D Global Biotech.
  • The company focuses on advancing clinical trials, new drug development, cancer prevention diagnostics, stem cell & exosome therapies, & distribution of post-market auxiliary products.
  • The announcement includes standard forward-looking statements warning of risks & uncertainties regarding future business plans & financial projections.